Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
|Videos|May 18, 2020
Supplements and Featured Publications
- Therapeutic Changes in HER2+ Breast Cancer
- Volume 1
- Issue 1
Novel Treatments in HER2-Positive Breast Cancer
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Advertisement
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Supported by an unrestricted educational grant by Daiichi Sankyo
Articles in this issue
Advertisement
Related to this article
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
3
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5